GLSI 10-Q: SEC filing
Greenwich LifeSciences
Filed with the SEC on · accession 0001493152-26-052438
GLSI filed a 10-Q (quarterly report) with the SEC on Nov 16, 2026. Greenwich LifeSciences filed its Q3 2026 10-Q quarterly report, reporting no revenue and continued net losses typical of a clinical-stage biopharmaceutical company.
Summary of the filing
Greenwich LifeSciences filed its Q3 2026 10-Q quarterly report, reporting no revenue and continued net losses typical of a clinical-stage biopharmaceutical company. The company remains focused on developing its GP2 immunotherapy product candidate.
Key details
✦ Ask GOAX AI about this filing — what it means for GLSI, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for GLSI?
Click hereFrequently asked questions
What did GLSI file with the SEC on Nov 16, 2026?
GLSI filed a 10-Q (SEC filing). Greenwich LifeSciences filed its Q3 2026 10-Q quarterly report, reporting no revenue and continued net losses typical of a clinical-stage biopharmaceutical company. The company remains focused on developing its GP2 immunotherapy product candidate.
How do I read a 10-Q?
The quarterly report: unaudited results for the quarter plus management’s comments. Compare revenue, margins and cash flow with the same quarter last year. Check MD&A for guidance changes and what drove the quarter.
Why are SEC filings important?
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 10-Q (quarterly report): The quarterly report: unaudited results for the quarter plus management’s comments.
Other GLSI SEC filings
Get alerts when GLSI files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days